There’s no doubt about it, working on a railroad can be tough on work boots. See how Dallas, Garland & Northeastern Railroad realized the importance of quality and durability when it came to protecting its crew with the right footwear for the job.

Mohawk is refreshing its popular RevWood line to represent recent product enhancements and evolving market demands. 

Accurate reporting of outcomes is crucial for interpreting the results of randomized controlled trials (RCTs). However, selectively reporting outcomes in publications to achieve researchers’ anticipated result… Read the full article ›

The post Impact of selective reporting bias on stroke trials: potential compromise in evidence synthesis – A cross-sectional study was curated by information for practice.

Vice President Kamala Harris has conceded the election, promising Americans that there will be a “peaceful transfer of power” and stressing loyalty “to our God,” while also promising to keep fighting.

By Gareth Hunt, freelance writer.

One of the world's most important currencies is information. That information could be about anybody and anything and may be used in a million different ways. With this much personal information people put on the internet, it becomes effortless for cyber criminals to get that information and perpetrate identity thefts.

UCLA investigators have shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve treatment outcomes for patients with small cell bladder cancer and small cell/neuroendocrine prostate cancer.

The Q resolution in Bonse–Hart double-crystal diffractometers is determined for a given Bragg angle by the value of the crystallographic structure factor. To date, the reflections Si 220 or Si 111 have been used exclusively in neutron scattering, which provide resolutions for triple-bounce crystals of about 2 × 10−5 Å−1 (FWHM). The Darwin width of the GaAs 200 reflection is about a factor of 10 smaller, offering the possibility of a Q resolution of 2 × 10−6 Å−1 provided crystals of sufficient quality are available. This article reports a feasibility study with single-bounce GaAs 200, yielding a Q resolution of 4.6 × 10−6 Å−1, six times superior in comparison with a Si 220 setup.

In a world of ever-advancing technology and development, many company heads often get lost in the bustle and get swept up in the sea of buzzwords that happen to be popular at any given moment. They ...

When a promising new drug to treat obesity was approved by the Food and Drug Administration for sale in the U.S. last month, it was the first such treatment to gain approval since 2014.

In clinical trials, weekly injections of semaglutide — or Wegovy, as it's been branded -- helped people drop an average of 15% of their body weight. That's an average of about 34 pounds over 16 months, before their weight plateaued, a far greater weight loss, obesity specialists say, than achieved with other drugs on the market. At least as important, Wegovy raised none of the alarm bells with the FDA or obesity doctors that it might trigger serious side effects of the sort experienced by some people taking fen-phen or some previous medical treatments for obesity.

But with a price tag for Wegovy of $1,000 to $1,500 a month, a very big question remains: Will insurers cover its significant cost for the many millions of people like Marleen Greenleaf, who might benefit?

Greenleaf grew up on the island of Trinidad, where her entire family paid little heed to what they ate and paid a high medical price, she says: "My husband has diabetes, my sister has diabetes, my brother has diabetes."

Since then, she's tried — and failed — at numerous diets, says Greenleaf, now 58 and an administrator at a charter school in Washington, D.C. Then, in 2018, she signed up for the clinical trial of a new drug — a once-weekly shot that changes the way her brain signals hunger.

A drug that finally stops her cravings

She noticed the change soon after her first injection of Wegovy: "For me, there was something that triggered in my brain to tell me that I was not hungry," she says. No more fierce cravings for the chocolate chip cookies she adores. Without the cravings she was able to slow down and reconsider the foods she'd been reaching for.

"I also wanted to eat healthier," she says. "I was looking at options, reading labels, looking at the calories — not just the calories, but also the sugar."

Over the 68-week research trial, Greenleaf dropped 40 pounds. Her blood pressure fell, which meant she qualified to donate her kidney to her husband, who was on dialysis.

"It was one of the best gifts of life that I could have ever given," she says.

But after that study ended, Greenleaf regained some of the weight. Wegovy is considered a long-term, possibly lifelong medication to treat chronic obesity. In the pre-marketing clinical studies, weight loss topped out at a total average weight loss of 15-18%, even as people continued to take the drug. And, as was the case with Greenleaf, once they stopped getting the weekly injections some of that weight came back.

Now, Greenleaf wants to resume the Wegovy shots.

"My only challenge actually is getting the insurance company to approve it," she says.

Reimbursement for obesity drugs' cost is patchy

Insurance coverage, it turns out, is a giant question — not just with Wegovy, but with obesity drugs in general. Some private insurers do include some prescription obesity drugs in the list of medicines they'll cover; it's too early to tell whether Wegovy will make those lists. Many doctors and patients are optimistic, because it is a higher dose of an existing diabetes medication called Ozempic, which is often covered by insurers.

A few select state Medicaid programs will cover medications that treat obesity, in some circumstances. But, significantly, Medicare does not cover obesity drugs — and many private insurers typically follow Medicare's lead.

Yet the demand for a good treatment is there, says Dr. Fatima Cody Stanford, a leading obesity researcher at Harvard. She was not involved in conducting the Wegovy clinical trial, but closely followed it. "I'm excited about it," she says, because of the dramatic weight loss.

The drug acts on the brain so people eat less and store less of what they eat. That helps address the excess weight as well as helping with numerous related diseases of the liver or heart, for example.

Why the FDA has been slow to approve obesity treatments

There is a long history of drugs that have looked like promising treatments for obesity, then failed. Decades ago, amphetamines, were prescribed, until their addictive properties became apparent. In the 1990s, the combination of fenfluramine and phentermine — administered as the diet drug fen-phen — was heavily marketed, only to later be pulled from the market for causing heart valve problems.

Those experiences and others have made physicians skeptical.

"In obesity medicine field, we've learned to be cautiously optimistic each time we have a new medication that looks promising," says Dr. Ihuoma Eneli, director of the Center for Healthy Weight and Nutrition at Nationwide Children's Hospital in Columbus, Ohio, who was not involved in the study of Wegovy.

So far, Eneli does not see any obvious concerns with the class of drugs that includes Wegovy, and calls the results so far "very promising." Wegovy is similar to another drug made by Novo Nordisk — Saxenda — which has been on the market since 2014, and which Eneli occasionally prescribes to her pediatric patients who are struggling with obesity.

In clinical research studies, the primary side effects reported after taking Wegovy affected the digestive system: nausea, diarrhea, vomiting, constipation, abdominal pain or intestinal infections.

Eneli says such side effects and their frequency are milder than the problems that have arisen in the past. That good safety profile may mean the drug is "less likely to come up with unanticipated risks," she says.

But, the new drug will be of little use, she and other doctors who treat obesity say, if it's not also affordable for patients.

"Before I even bring up that drug with my patients, I'm looking to see which insurance they are having on the left side of my screen — because that will determine whether I bring it up," Stanford, the Harvard physician, says. "If it's out of reach, like I said, I won't bring it up."

Stanford says her patients on existing obesity medications do extraordinary things to keep their coverage so they can afford to stay on the drugs.

"Several nurses here at the hospital that are my patients stayed working — they were supposed to retire — so they could stay on their injectable medication," Stanford says,"because that's how beneficial it was to them."

Why some are willing to pay out of pocket

Some people, like David Scheesley, 42, says he would consider paying for Wegovy, even if he had to pay the full sticker price. The Hanford, Calif., correctional officer has tried since 2019 to lose weight on various diets — low-fat, all-meat, all-vegetable — without success. His weight has led to other health concerns — with his blood fats and his heart — which makes Scheesley think of his 5-year-old son.

"I want to see him for a lot of years; I don't want to have a stroke," he says. "I don't want to have diabetes. I want to be there for him. So, for me personally, that [monetary cost] is not astronomical, if it can give me some more time."

Novo Nordisk, the company that makes Wegovy, is in talks with insurers, and acknowledges that ensuring health insurance coverage of its drug is critical. The challenge, says Douglas Langa, executive vice president of Novo Nordisk North America, is getting doctors, patients, and politicians to recognize obesity as a disease — and that therefore insurance should cover the cost of medicine to treat it.

"There's a medical component to [obesity] that needs to be recognized; this is a disease state like we should be treating any other disease state," Langa says. He says about 40% of private insurers cover Saxenda, the similar weight-loss medication the company makes.

Langa tells insurance companies this, making the case for why prescriptions for Wegovy should be covered. His company is also heavily lobbying Congress to pass legislation to allow Medicare to cover obesity medications. It makes sense from a financial perspective, he argues, because obesity is the root disease underlying so many other diseases.

"We do believe insurers understand that [untreated obesity] is a gateway into 60 other health conditions," Langa says. The need is hard to ignore, he adds. More than 100 million people in the U.S. alone struggle with obesity.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Recent strides in biotechnology offer the promise of new and innovative applications -- from edible vaccines to protein-based electronics components.

Given the current state of quantum computing and the significant challenges that still need to be overcome, it is highly unlikely that a quantum computer that can compromise public-key cryptography – a basis for the security of most of today’s computers and networks – will be built within the next decade, says a new report by the National Academies of Sciences, Engineering, and Medicine.

Biotechnology has the potential to be a part of the solution in protecting forest trees against destructive pest and disease outbreaks

New models for studying the human brain — human neural organoids, transplants, and chimeras — show promise for advancing understanding of the brain and laying the groundwork for new therapeutic approaches to brain diseases that have so far proved hard to treat, says a new report from the National Academies of Sciences, Engineering, and Medicine.

The emergence of biological physics as a field has had an impact on artificial intelligence, synthetic biology, the global response to COVID-19, and more. A new report outlines research directions and recommends ways federal agencies and universities can help strengthen the field’s future.

Maria Spiropulu and Michael Turner — co-chairs of a National Academies study underway to assess key science questions that will drive research in the field of elementary particle physics for the next decade and beyond — discuss the study, community engagement, and the field’s relevance to everyday life.

Flakes of graphene welded together into solid materials may be suitable for bone implants, according to a study led by Rice University scientists.

read more

More and more, customers expect to find cleaner-label options in every aisle of the grocery store, including the bread aisle. Sixty percent of bread consumers say the type of ingredients used in bread formulation is a primary consideration when purchasing.

Nuts, seeds and other inclusions add new dimensions of color, appearance, texture, nutrition, flavor and more to an increasing range of snack and bakery products. Nut and seed consumption has continued to increase over the past several years. One of the contributing factors to the growth is consumer awareness and interest in plant-based foods.

To help ensure a long-term sustainable red seaweed supply chain, Cargill has launched the Red Seaweed Promise.

With more consumers attending gatherings, the dessert category is having a renaissance. 

As consumers’ purchasing behaviors continue to impact the U.S. on-premise, experts note that the channel remains resilient amid fluctuating trends.

Promoting Equity Without Compromise: Dr. Ryan Smith's Perspective on Fair Grading Practices

The PHS Patient No-Show Predictor solution can help enhance the healthcare experience for both patients and caregivers alike by maximizing health outcomes, minimizing revenue loss and improving operational efficiencies.

The company aims to become a personalized digital coach for any diseases that require weight control.

Empowering Women to Lead Boldly: Join Africa's Top Female Changemakers in Nairobi for The Audacity Conference 2024—Uniting Aspiring and Established Leaders to Shape a Future of Equality and Progress. Join us from November 27th to 30th, 2024.

Award-winning fashion designer and fitness entrepreneur Victoria Napolitano is set to release her inspirational film, Ageless, which chronicles her remarkable journey of resilience and perseverance.

New research data offers much-needed hope for veterans wrestling with combat-associated posttraumatic stress disorder (PTSD). The study explores the use of hyperbaric oxygen therapy (HBOT) to address symptoms that persist despite standard treatments.

Breaking promises to yourself erodes self-trust. Learn how to build self-belief by keeping small commitments and transforming your habits.

The post Silent Saboteur: Why You Keep Breaking Your Own Promises first appeared on Chase Jarvis.

The post Silent Saboteur: Why You Keep Breaking Your Own Promises appeared first on Chase Jarvis.

New research data offers much-needed hope for veterans wrestling with combat-associated posttraumatic stress disorder (PTSD). The study explores the use of hyperbaric oxygen therapy (HBOT) to address symptoms that persist despite standard treatments.

This comprehensive pharmacogenomics eBook was curated for you to gain valuable knowledge and insights into the rapidly advancing field of precision medicin

A new study reports that daily use of cannabidiol (CBD) extends lifespan and improves symptoms of Leigh syndrome in both mice and human cellular models.

This comprehensive pharmacogenomics eBook was curated for you to gain valuable knowledge and insights into the rapidly advancing field of precision medicin

High-grade glioma (HGG), a type of aggressive brain cancer, accounts for the leading cause of cancer-related mortality for children and adolescents. 

Keith Doyle has written a guest blog post for "Brian Kelly's UK Web Focus: Reflections On The Web" blog [2007-06-05]

During Keith Doyle, Salford University talk, delegates will discover how, by taking the information architecture approach as their next step, they can improve the user experience and business benefits. Information architecture gives delegates a framework and benchmarks for managing web provision at an institutional level. This should be an engaging and entertaining talk which would help delegates decide whether a formal IA role is appropriate to their organisation. Helping delegates consider their institutional strategic approach: What is IA? How is the role covered at the moment? Should it be a specific post rather than something that's squeezed in with everything else we do?

The promise of proteomics for cancer prevention  Cancer Research UK News

Eternal Promise by Lee Bogle is a(n) Limited Edition. The Edition is Limited to Limited Edition of 250 pcs

A Promise Fulfilled Giclee on Canvas Deluxe by Harrison Ellenshaw is a(n) Limited Edition. The Edition is Limited to Edition of 95 pcs

A Promise Fulfilled H/E Giclee on Canvas Premiere by Harrison Ellenshaw is a(n) Limited Edition. The Edition is Limited to Edition of 10 pcs

A Promise Fulfilled H/E Giclee on Canvas Petite by Harrison Ellenshaw is a(n) Limited Edition. The Edition is Limited to Edition of 195 pcs

Artificial intelligence (AI) is one of the most promising — and exciting — technologies to come to the HVACR industry in a long time.

Hybrid systems offer a pathway that balances environmental concerns with practical considerations, ensuring a more sustainable and feasible transition towards cleaner energy sources.

Sarah Bowen of the Promise of Life Network crisis pregnancy center near Pittsburgh talked with me about the motivation behind the campaign by abortion advocates against the work these centers do, which is to provide women with support during an unplanned pregnancy. https://x.com/PAcatholic/status/1703790777099235616?s=20   https://fb.watch/nccvJtmh6p/?mibextid=cr9u03  

It is now well accepted that virtually all brands, from the utmost recognized to the newly eager, face an unprecedented onslaught of counterfeiting and gray market trading. In emerging countries, this menace is bold and audacious, with outright fakes appearing in the open marketplace. In developed countries, the problem is equally insidious due to online propagation of counterfeit products through e-commerce platforms.

Justin had the news from the People's Bank of China here on Monday:

• PBOC governor will maintain yuan exchange rate at a reasonable, balanced level

The PBOC governor Pan Gongsheng emphasized that the Bank will not let the yuan plummet without a fight:

• Will step up countercyclical adjustment
• Should resolutely guard against the risk of exchange rate overshoot

Today is an example of the Bank pushing back on yuan weakness, with the reference rate set 300+ points stronger for the CNY than was expected (in the Reuters model).

Offshore yuan has jumped (lower USD/CNH as shown in the chart below):

Trump tried to ban the social media platform the last time he was in the White House.